CD8A and malaria: In individuals immunized using sporozoites-based vaccines, such as, circumsporozoite protein-specific monoclonal antibodies, immunity to clinical malaria, and sterile protection involving humoral and CD8+ T cell-based responses are achievable at high antibody titer (Olotu et al. 2013; Hopp and Sinnis 2015; Livingstone et al. 2021).